Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 34 recruiting now early-phase tilt

Colon Cancer: early-phase trial registry

34 of 99 indexed Colon Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #140 of 28,707 conditions by registered trial count.

99 US clinical trials · 34 currently recruiting · #140 of 28,707 conditions by registered trial count

Colon Cancer: 99 US clinical trials tracked, 34 recruiting.

Colon Cancer is the subject of 99 registered US clinical trials on ClinicalTrials.gov, 34 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.

Enrollment posture brief

Registry condition colon-cancer

OPEN 34 | RECR 34% | LATE 4 | EARLY 37 | RANK #140 | SPON 6

Nearest open-share peer: Stage IIIB Lung Cancer AJCC v8 (34% recruiting · 32 trials)

Pregnancy Related56%Prostate Adenocarcinoma45%Systemic Lupus Erythematosus43%Spinal Cord Injury38%Colon Cancer (this)34%
Open-enrollment share among volume-matched conditions near Colon Cancer

Colon Cancer lists 34 open slots (34% of 99 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colon Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colon Cancer is recruiting below its size-band peers.

    34 of 99 indexed trials (34.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colon Cancer trials is spread across many organizations.

    National Cancer Institute (NCI) accounts for 6 of 99 trials (6.1%). 73 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colon Cancer enrolment sits around 110 participants.

    Median target enrolment is 110 among the 98 trials that report a genuine target (sentinel values excluded). 45 of those (45.9%) plan for fewer than 100 participants.

  4. Colon Cancer research is mostly interventional.

    76 interventional and 23 observational studies make up this index (76.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 126Phase 211Phase 34

Open and recent trials

99 total, page 2 of 2

ACTIVE NOT RECRUITING 51 participants

A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors

Memorial Sloan Kettering Cancer Center

NCT03432806

ACTIVE NOT RECRUITING Phase 1 50 participants

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Anup Kasi

NCT05121038

ACTIVE NOT RECRUITING Phase 2 48 participants

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

University of Colorado, Denver

NCT04963283

ACTIVE NOT RECRUITING Phase 1 44 participants

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

HUYABIO International

NCT05485974

ACTIVE NOT RECRUITING Phase 1 42 participants

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Immunophotonics

NCT05688280

ACTIVE NOT RECRUITING Phase 1 24 participants

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

M.D. Anderson Cancer Center

NCT05722327

ACTIVE NOT RECRUITING NA 20 participants

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

City of Hope Medical Center

NCT02293954

ACTIVE NOT RECRUITING NA 20 participants

Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors

Wake Forest University Health Sciences

NCT06340503

ACTIVE NOT RECRUITING Phase 1 14 participants

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

GlaxoSmithKline

NCT06710847

ACTIVE NOT RECRUITING NA 7 participants

Oncology Episode Payment Model in Hawaii

University of Pennsylvania

NCT03523546

COMPLETED 200,000 participants

General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)

University Hospitals Cleveland Medical Center

NCT00622557

COMPLETED NA 5,460 participants

Mailed FIT Outreach 2022

Abramson Cancer Center at Penn Medicine

NCT05341622

COMPLETED NA 2,004 participants

Study of Colorectal Cancer Screening Options

Kaiser Permanente

NCT05987709

COMPLETED NA 1,900 participants

Adherence to Colon Cancer Screening (ACCS)

Ohio State University Comprehensive Cancer Center

NCT02112747

COMPLETED NA 1,831 participants

Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making

University of North Carolina, Chapel Hill

NCT01558583

COMPLETED NA 1,267 participants

Patient Navigator Project

H. Lee Moffitt Cancer Center and Research Institute

NCT00375024

COMPLETED Phase 3 621 participants

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

Norgine

NCT02254486

COMPLETED NA 500 participants

Impact of a Novel Patient Educational Booklet on Colonoscopy Quality

VA Greater Los Angeles Healthcare System

NCT00975247

COMPLETED Phase 3 386 participants

BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

Braintree Laboratories

NCT00756548

COMPLETED NA 375 participants

Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer

Wake Forest University Health Sciences

NCT01656044

COMPLETED NA 302 participants

Men Together Making a Difference: Health Promotion for Black Men

University of Pennsylvania

NCT02572414

COMPLETED NA 284 participants

Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer

Ohio State University Comprehensive Cancer Center

NCT01801059

COMPLETED NA 238 participants

Quad Resection (Hot Snare vs Cold Snare vs Hot EMR vs Cold EMR)

Indiana University

NCT03462706

COMPLETED Phase 1 229 participants

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma

NCT02632448

COMPLETED Phase 1 202 participants

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Amgen

NCT00625651

COMPLETED NA 183 participants

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Kaiser Permanente

NCT03291951

COMPLETED NA 180 participants

Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy

VA Office of Research and Development

NCT01639443

COMPLETED NA 178 participants

Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting

University of California, Davis

NCT01729416

COMPLETED 120 participants

Understanding the Value of Community Vital Signs in Primary Care

Virginia Commonwealth University

NCT02512835

COMPLETED 115 participants

GI SPORE Colon Biosample Protocol

University of Michigan

NCT02243267

COMPLETED Phase 1 107 participants

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Novartis Pharmaceuticals

NCT01068483

COMPLETED 93 participants

Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients

M.D. Anderson Cancer Center

NCT00508846

COMPLETED NA 85 participants

Latino Peers as Patient Navigators for Colon Cancer Screening

Icahn School of Medicine at Mount Sinai

NCT02226107

COMPLETED Phase 3 69 participants

An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy

Corewell Health West

NCT00467922

COMPLETED NA 52 participants

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Washington University School of Medicine

NCT05427214

COMPLETED Phase 1 50 participants

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

David Bajor, MD

NCT02861300

COMPLETED Phase 2 48 participants

Clinical Trial in Patients With Metastatic Colorectal Cancer

Mast Therapeutics

NCT00081627

COMPLETED Phase 3 46 participants

Promoting Physical Activity After Colorectal Cancer

The Miriam Hospital

NCT00230646

COMPLETED NA 40 participants

Hybrid APC Assisted EMR for Large Colon Polyps

Milton S. Hershey Medical Center

NCT03390907

COMPLETED NA 30 participants

Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors

University of Michigan Rogel Cancer Center

NCT04827459

COMPLETED 29 participants

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

UNC Lineberger Comprehensive Cancer Center

NCT01789983

COMPLETED 25 participants

Genetic Investigation of Solid Tumors Cohort

Scripps Translational Science Institute

NCT01005225

COMPLETED Phase 1 23 participants

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals

NCT03199586

COMPLETED 22 participants

Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance

National Human Genome Research Institute (NHGRI)

NCT02767986

COMPLETED Phase 2 20 participants

Clinical and Translational Study of STA-9090

Memorial Sloan Kettering Cancer Center

NCT01111838

COMPLETED Phase 2 20 participants

Cellular Immune Augmentation in Colon and Rectal Cancer

University of California, Irvine

NCT00257322

COMPLETED Phase 1 11 participants

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Cancer Institute (NCI)

NCT03384316

COMPLETED Phase 2 10 participants

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

National Cancer Institute (NCI)

NCT03801915

COMPLETED Phase 2 5 participants

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

St. Luke's-Roosevelt Hospital Center

NCT01163552

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 26
Phase 2 11
Phase 3 4

Named interventions

Most-linked intervention names on Colon Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cemiplimab Drug
2 trials
Receiving an educational booklet Other
1 trials
Predictive no-show overbooking Other
1 trials
Sleep Coach App Behavioral
1 trials
Halcyon 4.0 system Device
1 trials
Community vital signs Other
1 trials
No Text Behavioral
1 trials
Standard Mail Behavioral
1 trials

US sites by state

Facility locations filed on Colon Cancer trials. A trial with sites in several states counts in each.

California 27 trials
New York 18 trials
Texas 16 trials
Michigan 15 trials
Maryland 14 trials
Colorado 12 trials
Florida 10 trials
Ohio 9 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colon Cancer page

99 registered trials, 34 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colon Cancer condition card totals 99 registered trials; most-linked intervention Cemiplimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.